期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 91, 期 4, 页码 607-620出版社
WILEY
DOI: 10.1038/clpt.2011.325
关键词
-
资金
- Abbott
- Amgen
- Inova
- Merck
- Pfizer
- Roche
- Schering-Plough
- UCB
- Wyeth
- Bristol-Myers Squibb
- Euroimmun AG
Progress in understanding the cellular and molecular mechanisms of rheumatoid arthritis (RA), together with the availability of new therapies, has changed the way we think about RA. The paradigm shift in RA therapy has been from controlling symptoms to controlling the disease process with the abrogation of inflammation. Challenges that are still unresolved include the issues in disease prevention, treatment specificity to restore tolerance, approaches to facilitate tissue repair, and treatment optimization to fit the individual patient's disease phenotype and comorbidity context. This review summarizes the pathogenesis-related rationales for the current therapeutic strategies in RA and for emerging therapies and potential approaches to restoring immune tolerance in RA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据